Compare DexCom, Inc. (DXCM) vs Iris Energy Limited (IREN) Price & Performance

DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.

The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.

IREN trades at $43.24, up 11.62% in 24 hours, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 revenue of $501.02M and net income of $86.94M, but missed EPS estimates for three consecutive quarters. Recent news highlights a $2.8B AI contract surge and a raised revenue target above $4B, driving investor optimism despite high valuation ratios like a P/E of 51.6.

Outlook is mixed: strong AI contract growth and analyst consensus price target of $84.43 suggest upside, but execution risks, high valuations, and consistent earnings misses pose challenges. Stock sentiment is buoyed by institutional interest, including a new position by California State Teachers Retirement System in Q2 2026.